Study of CLN-978 for people with systemic lupus erythematosus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus (SLE) for at least 6 months
- Your lupus must be active, with a score of 6 or more on a lupus activity scale (SLEDAI)
- You must have tried at least two different lupus treatments (like steroids, hydroxychloroquine, immunosuppressants, or biologics) and they did not work well enough
- You must have certain lupus-related antibodies in your blood (like ANA, anti-dsDNA, or anti-Sm)
- You must have enough immune cells in your blood, including B cells (at least 25 per microliter) and lymphocytes (at least 500 per microliter)
- Your kidney, liver, and blood cell counts must be within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that helps your immune system target and destroy disease-causing B cells. It's for people with moderate to severe Sjögren's disease who haven't had success with other treatments.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.